Drug news
Merck Inc files "rolling submission" to FDA for MK 3475 for Advanced Melanoma.
Merck has started a rolling submission to the FDA of a Biologics License Application for MK-3475, the company's investigational anti-PD-1 immunotherapy, for patients with advanced Melanoma who have been previously treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company expects to complete the application in the first half of 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins